Our Melanoma Clinical Trial is Now Enrolling: NCT05470283
The University of Texas MD Anderson Cancer Center is currently enrolling patients in a Phase 1 clinical trial of OBX-115, which is being evaluated in patients with metastatic melanoma.
OBX-115 is an investigational cell therapy comprised of TILs genetically engineered to express membrane-bound IL15, a cytokine that is designed to remove the need for concomitant IL2 therapy, a toxic and costly requirement for conventional TILs.
One of the primary objectives of the Phase 1 clinical trial is to assess its safety, tolerability, and preliminary efficacy in patients with metastatic melanoma who have previously received other anti-cancer therapies.
Please contact email@example.com for more information.
OBX-115 is a novel engineered tumor-infiltrating lymphocyte (TIL) therapy armed with regulated membrane-bound IL15 that is designed to remove the need for concomitant IL2 therapy, a toxic and costly requirement for conventional TILs.
Preclinical data have demonstrated enhanced TIL persistence, potency and improved tumor control compared to unengineered TILs, which is anticipated to improve clinical outcomes in patients suffering from different types of solid tumors.
Benefits of TIL-endogenous mbIL15 vs. systemic IL2:
TIL expansion & persistence
Drive adjacent NK cell
expansion & activity
Drive phenotype towards
CD8+ and memory T-cells
Unlike IL2, suppresses activation-induced cell death, doesn’t expand immunosuppressive Tregs or cause capillary leak syndrome-associated toxicity